Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-180-5 | CAS number: 79-14-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Immunotoxicity
Administrative data
Description of key information
NOEL (immunotoxicity): 600 mg/kg bw/day (male/female). The NOEL is based on 100% glycolic acid dosed (adjusted for 70% purity of the test substance).
There were no treatment-related adverse effects on spleen or thymus and glycolic acid 70% solution did not affect the primary humoral immune response to SRBC.
Key value for chemical safety assessment
Effect on immunotoxicity: via oral route
Link to relevant study records
- Endpoint:
- immunotoxicity: sub-chronic oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Guideline compliant Commission Directive 87/302/EEC, U.S. EPA Pesticide Assessment Guidlines Subdivision F, 82-1 ( 1982), OECD Test Guideline 407, Maff Japan NohSan No. 4200 ( 1985). This study was selected as the key study because the information provided for the hazard endpoint is sufficient for the purpose of classification and labelling and/or risk assessment.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EPA OPPTS 870.7800
- Principles of method if other than guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicology in Rodents)
EPA OPP 82-1 (90-Day Oral Toxicology). - GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD (SD) IGS.BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Raised by: Charles River Laboratories, Inc., Raleigh, North Carolina, USA
Birthdated 18 August 1998. Rats were circa 5 weeks old at time of receipt. Group mean bodyweight range at time of allocation to study was 229.5 to 232.6g for males and 163.7 to 165.0g for females.
- Age at study initiation: 48 days
- Housing: all rats were housed one per cage, sexes separate, in stainless steel, wire-mesh cages suspended above cage boards.
- Diet (e.g. ad libitum): All rats were fed PMI Nutrition International, Inc. Certified Rodent Checkers LabDiet@ 5002 ad libitum.
- Water (e.g. ad libitum): Tap water was provided ad libitum
- Acclimation period: Upon arrival at Haskell Laboratory, the rats were quarantined for six days of the 13-day pretest period.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23" +/- 1°C
- Humidity (%): 50% +/- 10%
- Photoperiod (hrs dark / hrs light): 12-hour light/dark cycle (fluorescent light) - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Dose solutions were prepared at 15, 30 and 60 mg/mL on a daily basis and administered on same day by gavage in a dose volume of 10 mL/kg bw.
The solutions were administered daily by oral gavage at a dose volume of 10 ml/kg, to achieve dose levels of 150, 300, and 600 mg/kg/day, based on the most recently recorded weight. Dosing solutions were stored refrigerated until used. Dosing solutions stored beyond 14 days after preparation were not administered to animals. Control animals were dosed with commercially-supplied water only. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- HPLC: Hewlett-Packard 1090; UV 210 nm; column: Zorbax® SB-C18, 4.6 mm x 150 mm; 40°C mobile phase: 2.0% acetonitrile/98.0% 3.1 mM H3P04; 1.0ml/min., Injection volume: 4.0 µl
From each dosing solution sample, 1 mL was aliquoted and diluted to 10 mL with high performance liquid chromatography (HPLC) grade water, then mixed. The 0 mg/mL and 15 mg/mL solutions were analyzed without further dilution. The 30 mg/mL and 60 mg/mL samples were further diluted with HPLC grade water to an expected concentration of 1.5 mg/mL active ingredient (a.i.) prior to analysis. Samples submitted for analysis were analyzed the day the solutions were prepared by the testing group. - Duration of treatment / exposure:
- 28 days animals were sacrificed on day 29
- Frequency of treatment:
- Daily
- Remarks:
- Doses / Concentrations:
150, 300 or 600 mg/kg bw 15, 30 and 60 mg/mL administered in 10 mL/kg bw volume of water
Basis:
nominal in water - No. of animals per sex per dose:
- 10/sex/dose level
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- See study design table in "other information section".
- Dose selection rationale: Dose levels for this study were selected based on results from a developmental toxicity study in which glycolic acid was administered by gavage to Crl:CD%R female rats (25/group) on days 7-21 of gestation at daily dose levels of 0, 75, 150, 300, or 600 mg/kg/day.
- Rationale for animal assignment (if not random): Rats were selected for study use on the bases of adequate body weight gain, freedom from any
clinical signs of disease or injury, and a body weight within 20% of the mean within a sex. The selected rats were distributed by computerized, stratified randomization so that there were no statistically significant differences among group body weight means within a sex.
- On test day 23, animals designated for immunotoxicity evaluation were injected intravenously in the lateral tail vein with 0.5 mL of 4x108 Sheep Red Blood Cells (SRBC)/mL. Six days after injection, on test day 29, the animals were euthanized by carbon dioxide anesthesia and exsanguination. Following sacrifice, the spleen and thymus were removed from each rat and weighed and serum was collected from each rat and analyzed for SRBC-specific IgM antibody. Sera previously collected from rats injected with SRBC and dosed with the known immunosuppressive agent cyclophosphamide were
analyzed for SRBC-specific IgM antibody concurrently with the study samples as a positive control. - Observations and clinical examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Cage-site examinations to detect moribund or dead rats and abnormal behavior and appearance among rats were conducted at least once daily throughout the study. Moribund and dead rats were submitted for a gross and microscopic examination. At every weighing, each rat was
individually handled and examined for abnormal behavior and appearance. Rats designated for neurotoxicity evaluations had cage-site examinations approximately one to two hours after dosing on test day 1, and approximately one to two hours after dosing on one day during the weeks that the functional observational battery was conducted.
BODY WEIGHT: Yes
- Time schedule for examinations: All rats were weighed once per week during the 90-day feeding phase of the study. In addition, the neurotoxicity substudy rats were weighed on the days of neurotoxicity evaluation.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)/ FOOD EFFICIENCY
The amount of food consumed by each rat over each weighing interval was determined throughout the study. From these determinations and body weight data, mean daily food consumption and mean food efficiency were calculated. - Sacrifice and pathology:
- Day 29 / thymus + spleen weights.
Sera collected for ELISA for SRBC
GROSS PATHOLOGY: Yes- spleen and thymus
HISTOPATHOLOGY: Yes - spleen and thymus - Humoral immunity examinations:
- - Humoral Immune Function and Immune Organ Weights
- Test day 23, 10 animals/sex/dose injected iv w/ Sheep Red Blood Cells.
- Test day 29 animals sacrificed
- Spleen and Thymus removed and weighed
- Serum collected and analyzed for IgM antibody
There were no statistically significant differences in the primary humoral immune response to SRBC for male or female rats at any dosage of glycolic acid in this study.
A statistically significant decrease compared to control of 56% and 66%, respectively, in the primary humoral immune response to SRBC was observed for male and female rats dosed for six days with 20mg/kg/day cyclophosphamide, the positive control material. Therefore, the SRBC-specific ELISA test system was valid for this sutdy with glycolic acid. - Other functional activity assays:
- No further information.
- Other examinations:
- No further information.
- Positive control:
- A positive control study involved collecting sera from animals previously injected with SRBC and the immunosuppressive agent, Cyclophosphamide. Serum was analysed for SRBC-specific IgM antibody.
- Statistics:
- No further information.
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Ophthalmological findings:
- effects observed, treatment-related
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Details on results:
- A statistically significant decrease of 17% compared to control in mean absolute spleen weight was observed for the 600 mg/kg/day male dose group sacrificed at day 29. The decreased spleen weight for the 600 mg/kg/day male dose group, however, was considered secondary to test-substance induced lower mean body weight, and, therefore, was not considered an immunotoxic effect. No statistically significant alterations in either the mean absolute or relative spleen and thymus weights were observed in male and female rats at any dosage. Therefore, glycolic acid did not produce test-substance-related adverse effects on the spleen or thymus weights of either male or female rats.
There were no statistically significant differences in the primary humoral immune response to SRBC for male or female rats at any dosage of glycolic acid in this study.
A statistically significant decrease compared to control of 56% and 66%, respectively, in the primary humoral immune response to SRBC was observed for male and female rats dosed for six days with 20mg/kg/day cyclophosphamide, the positive control material. Therefore, the SRBC-specific ELISA test system was valid for this sutdy with glycolic acid. - Cell viabilities:
- effects observed, treatment-related
- Humoral immunity examinations:
- effects observed, treatment-related
- Specific cell-mediated immunity:
- effects observed, treatment-related
- Non-specific cell-mediated immunity:
- effects observed, treatment-related
- Other functional activity assays:
- effects observed, treatment-related
- Other findings:
- effects observed, treatment-related
- Dose descriptor:
- NOEL
- Effect level:
- 600 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: There were no treatment-related adverse effects on spleen or thymus and glycolic acid 70% solution did not affect the primary humoral immune response to SRBC.
- Conclusions:
- No test-substance -related adverse effects on spleen or thymus were observed in this study. Glycolic acid did not decrease the primary humoral immune response to SRBC of either male or female rats. Based on these data, the immune system does not appear to be a primary target of toxicity for glycolic acid in rats. Under the conditions of this study, the NOEL for immunotoxicology endpoints for both male and female rats was 600 mg/kg/day glycolic acid, the highest dosage tested. Under the conditions of this study, the NOEL for immunotoxicology endpoints for noth male and female rats was 600 mg/kg/day glycolic acid, the highest dosage tested. The study and the conclusions which are drawn from it fulfill the quality criteria (validity, reliability, repeatability).
- Executive summary:
No test-substance -related adverse effects on spleen or thymus were observed in this study. Glycolic acid did not decrease the primary humoral immune response to SRBC of either male or female rats. Based on these data, the immune system does not appear to be a primary target of toxicity for glycolic acid in rats.
Under the conditions of this study, the NOEL for immunotoxicology endpoints for noth male and female rats was 600 mg/kg/day glycolic acid, the highest dosage tested.
Reference
A. Organ Weights
-A statistically significant decrease of 17% compared to control in mean absolute spleen weight was observed for the 600 mg/kg/day male dose group sacrificed at day 29. The decreased spleen weight for the 600 mg/kg/day male dose group, however, was considered secondary to test substance induced lower mean body weight, and, therefore, was not considered an immunotoxic effect. No statistically significant alterations in either the mean relative spleen and thymus or absolute thymus weights were observed in male rats at any dosage. No statistically significant differences in either the mean absolute or relative spleen and thymus weights were observed in female rats at any dosage. Furthermore, glycolic acid did not produce test substance-related alterations in splenic or thymic histopathology at any dosage in either male or female rats following 90 days of exposure. Therefore, glycolic acid did not produce test substance-related adverse effects on the spleen or thymus weights of either male or female rats.
B. Humoral Immune Function
- There were no statistically significant differences in the primary humoral immune response to SRBC for male or female rats at any dosage of glycolic acid in this study. - A statistically significant decrease compared to control of 56% and 66%, respectively, in the primary humoral immune response to SRBC was observed for male and female rats dosed for six days with 20 mg/kg/day cyclophosphamide, the positive control material. Therefore, the SBC-specific ELISA test system was valid for this study with glycolic acid.
Additional information
Immune function organ weights were recorded in a 90-day sub-chronic rat oral toxicity study. A decrease in mean absolute spleen weight was observed for the 600 mg/kg/day male dose group. This was considered secondary to test substance induced lower mean body weight, and therefore not considered to be an immunotoxic effect. No statistically significant alterations in either the mean relative spleen and thymus or absolute thymus weights were observed in treated male rats. No statistically significant differences in either the mean absolute or relative spleen and thymus weights were observed in treated female rats. Furthermore, glycolic acid did not produce test substance-related alterations in splenic or thymic histopathology at any dosage in either male or female rats following 90 days of exposure. Therefore, glycolic acid did not produce test substance-related adverse effects on the spleen or thymus weights of either male or female rats.
There were no statistically significant differences in the primary humoral immune response to Sheep Red Blood Cells (SRBC) for any glycolic acid treated male or female rats. A statistically significant decrease compared to control of 56% and 66%, respectively, in the primary humoral immune response to SRBC was observed for male and female rats dosed for six days with 20 mg/kg/day cyclophosphamide, the positive control material. Therefore, the SBC-specific ELISA test system was valid for this study with glycolic acid.
Justification for classification or non-classification
No classification for immunotoxicity required since no effects on the immune system were observed. On this basis, Glycolic acid does not warrant any classification according to Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.